跳至主要内容
临床试验/JPRN-UMIN000012715
JPRN-UMIN000012715已完成未知

Clinical research of Alesion ophthalmic solution in patients with seasonal allergic conjunctivitis - Clinical research of Alesion ophthalmic solution in patients with seasonal allergic conjunctivitis

Medical company "Keisyo Kai"0 个研究点目标入组 260 人开始时间: 2014年1月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
260

研究概览

简要总结

At the time of pollen dispersal peak, epinastine hydrochloride ophthalmic solution significantly controlled itch sensation, patient-reported outcomes, objective symptoms, total score of QOL (JACQLQ), and aggravation/severity of symptoms scored in QOL in the prior treatment group, compared with the standard treatment group. Based on the above result, it was considered that use of epinastine hydrochloride ophthalmic solution at early timing kept symptoms mild and is effective.

研究设计

研究类型
Interventional

入排标准

年龄范围
12years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Patients using contact lenses with difficulty in use of ophthalmic solution 2. Patients given immunotherapy (hyposensitization therapy, modulated therapy) 3. Patients with surgical history in the internal eye (including laser therapy) within 3 months prior to enrollment 4. Patients with allergy to drugs (including fluorescein) to be used during the research 5. Patients taking medicines (including steroid and immunosuppressive drugs) which affects the efficacy of study drug within 14 days prior to enrollment (patients can use drugs except for steroid and immunosuppressive drugs unless amount of drug is changed during the research) 6. Pregnant women, women of child-bearing potential or lactating women

研究者

发起方
Medical company "Keisyo Kai"

相似试验